Charlie Hilton, born 20th October 1998 was 13 years old when diagnosed in August 2012 with a rare and aggressive form of cancer called Desmoplastic Small Round Cell Tumour, DSRCT. He went through intense chemotherapy along with 3 surgeries in order to drain fluid and to remove the cancer. Next he had an intense course of radiotherapy and in August 2013 was given the all clear, which meant he was in remission!
Just as we thought everything was going well… December 2013, he spent Christmas in hospital feeling unwell. In January 2014 we got the news that he had relapsed. He started a new type of chemotherapy which seemed to be effective. In August 2014 we were told the treatment had stopped working and the cancer had grown and there was nothing else they could do apart from giving as long a time as possible on palliative chemotherapy. This meant that his cancer was terminal!
On 22nd July 2015 at 2.55 am Charlie gained his handsome wings and is now the brightest star in the sky. Charlie’s Wish is in loving memory of Charlie and to keep his name alive. We want to raise money and awareness for his rare and aggressive cancer. Charlie was such a brave lad who had a smile for everyone, he always thought of others before himself. Charlie will forever and always be our brave boy
This site has been set up as we are looking to become a registered charity, but to do that we have to collect £5000 per year in donation this includes fundraising, buying merchandise from our Merchandise page, we need all the help we can get so plz dig deep into your pockets and donate all you can, plz visit the Merchandise tab at the top of the page to make a purchase
Thank you! ......................... admin@charlieswishcharity.co.uk
Heading 1
Heading 1
Info about Desmoplastic Small Round Cell Tumor
Desmoplastic small round cell tumor (DSRCT) was first described in 1989 by Gerald and Rosai who described a distinct type of small round blue cell tumor with a predilection for serosal surfaces such as the peritoneum and the tunica vaginalis that affected mostly Caucasian males in the second or third decade of life.1 DSRCT is generally associated with aggressive features and a poor prognosis. Tumor cells co-express epithelial, mesenchymal and neuronal markers and are thought to originate from a mesothelial or submesothelial progenitor cell with the potential to undergo multilineage differentiation. Because of this, DSCRT is also called "mesothelioblastoma". To date more than two hundred cases have been described in the medical literature. DSRCT exhibits a male predominance of 90%, and 85% of patients are Caucasian. Median age at diagnosis has been reported as 14, 19 and 25 years of age in different series.1-4 Several treatment modalities are used including surgery, radiotherapy and chemotherapy. Unfortunately, these modalities frequently do not provide a durable response, and the prognosis for patients with DSRCT remains poor. Despite aggressive therapy, 3-year overall survival has been estimated at 44% and the 5-year survival rate remains around 15%.5
